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Objectives This study tested whether interleukin (IL)-17A is involved in the pathogenesis of mouse myocardial ischemia/
reperfusion (I/R) injury and investigated the mechanisms.
Background Inflammatory processes play a major role in myocardial I/R injury. We recently identified IL-17A as an important
cytokine in inflammatory cardiovascular diseases such as atherosclerosis and viral myocarditis. However, its role
in myocardial I/R injury remains unknown.
Methods The involvement of IL-17A was assessed in functional assays in mouse myocardial I/R injury by neutralization/
repletion or genetic deficiency of IL-17A, and its mechanism on cardiomyocyte apoptosis and neutrophil infiltra-
tion were further studied in vivo and in vitro.
Results Interleukin-17A was elevated after murine left coronary artery ligation and reperfusion. Intracellular cytokine staining
revealed that T lymphocytes but not CD4 helper T cells were a major source of IL-17A. Anti–IL-17A monoclonal
antibody treatment or IL-17A knockout markedly ameliorated I/R injury, as demonstrated by reduced infarct size,
reduced cardiac troponin T levels, and improved cardiac function. This improvement was associated with a reduction
in cardiomyocyte apoptosis and neutrophil infiltration. In contrast, repletion of exogenous IL-17A induced the opposite
effect. In vitro study showed that IL-17A mediated cardiomyocyte apoptosis through regulating the Bax/Bcl-2 ratio,
induced CXC chemokine-mediated neutrophil migration and promoted neutrophil-endothelial cell adherence through
induction of endothelial cell E-selectin and inter-cellular adhesion molecule-1 expression.
Conclusions IL-17A mainly produced by T cells plays a pathogenic role in myocardial I/R injury by inducing cardiomyocyte
apoptosis and neutrophil infiltration. (J Am Coll Cardiol 2012;59:420–9) © 2012 by the American College of
Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.10.863n
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tThe rapid restoration of blood flow through the occluded
coronary artery by mechanical or pharmacological interven-
tion is the most effective therapy to limit infarct size and
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accepted October 11, 2011.improve the clinical outcome after acute myocardial infarc-
tion (1). However, reperfusion after ischemia itself causes
additional cardiomyocyte death and increases infarct size in
a process called myocardial ischemia/reperfusion (I/R) in-
jury. Potential mediators of reperfusion injury include oxi-
dative stress and inflammation (2).
Interleukin (IL)-17A is a member of the IL-17 family,
which includes six structurally related isoforms: IL-17A,
IL-17B, IL-17C, IL-17D, IL-17E, and IL-17F (3). Mul-
tiple cell types, including CD4  T cells,  T cells,
atural killer cells, and neutrophils, produce IL-17A (4).
nterleukin-17A acts on a variety of cells through its
biquitous receptors, IL-17RA and IL-17RC, and is a
ritical mediator of neutrophil recruitment and migration
hrough the induction of granulopoiesis and the production
f neutrophil chemokines, including lipopolysaccharide-
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chemoattractant (KC), and macrophage inflammatory
protein-2 (MIP-2) (5).
IL-17A plays an important role in host defense and
mediates autoimmune diseases (6). We and others have
reported that IL-17A is linked to the pathogenesis of several
cardiovascular diseases, including atherosclerosis (7–9), hy-
pertension, viral myocarditis, and dilated cardiomyopathy
(7–12). Recently, IL-17A has also been found to contribute
to brain, kidney, and intestine I/R injury (13–15), but the
mechanisms involved are still largely unknown.
In this study, we investigated the expression of IL-17A in
reperfused ischemic myocardium and the subsets of IL-
17A–releasing cells and characterized the functional in-
volvement of IL-17A in myocardial I/R injury. We show
that IL-17A is largely produced by T cells and plays a
pathogenic role in myocardial I/R injury by inducing cardi-
omyocyte apoptosis and neutrophil infiltration.
Methods
The Methods section is available in the Online Appendix.
Results
IL-17A increases after myocardial I/R injury. To test the
involvement of IL-17A in myocardial I/R injury, we first
investigated IL-17A levels in the myocardium at different
reperfusion time points after I/R. IL-17A messenger ribo-
nucleic acid (mRNA) and protein expression increased
significantly as early as 1 h after reperfusion, rose progres-
sively until 24 h, and then began to decrease, although it
remained at a high level compared with the sham group
until 72 h after I/R (Online Figs. 1A and 1B).
In addition to Th17 cells, T cells, natural killer cells,
nd neutrophils were reported to secret IL-17A (4). To
dentify which leukocytes were responsible for the elevation
f IL-17A in myocardial I/R, we used intracellular cytokine
taining combined with staining for various surface markers.
ver 95% of the IL-17A–secreting leukocytes were CD3
T cells, including approximately 70%  T cell receptor-
positive (TCR) cells and 13% CD4 cells, indicating
that T cells rather than Th17 cells were the major source
of IL-17A (Online Fig. 1C). Natural killer cells and
neutrophils comprised only a minor proportion of IL-17A-
secreting leukocytes. After 24 h of reperfusion, there was a
marked increase in the myocardial content of T cells.
imultaneously, the percentage of IL-17 TCR cells
elative to T cells also increased (Online Tables 1 and 2).
hese results suggest that myocardial I/R led to an increase
ot only in the number of infiltrated T cells but also in
the IL-17A production of these cells, which accounted for
a large part of the elevated myocardial IL-17A.
The IL-17 family consists of 5 members, including
IL-17A. Among these, IL-17F has the highest degree of
homology with IL-17A and exerts similar effects but to a
lesser extent (8). We therefore also examined mRNA pexpression of IL-17B, C, D, E,
and F in hearts after I/R. The
level of IL-17A mRNA was
much higher than that of the
other IL-17 family members, ap-
proximately 5-fold greater than
that of IL-17F (Online Fig. 2).
Neutralization of endogenous
IL-17A protects against whereas
repletion of exogenous IL-17A ex-
acerbatesmyocardial I/R injury. To
determine the causative role of IL-
17A in the development of myo-
cardial I/R injury, we treated the
myocardial I/R mice systemically
with neutralizing anti–IL-17A
monoclonal antibody (mAb) or
recombinant IL-17A before reper-
fusion. Interleukin-17A expression
reached a peak at 24 h after myo-
cardial I/R and remained elevated
for 72 h; therefore, we measured
infarct size at 1 day or 3 days after
reperfusion. The ratio of area at
risk (AAR) to left ventricle (LV)
area was the same in experimental
and control groups at both time
points, indicating that ligature was
reproducibly performed at the
same level of the left anterior cor-
onary artery. However, the ratio of
infarct area to AAR was signifi-
cantly lower in mice treated with
anti–IL-17A mAb relative to
those treated with isotype and
greater in mice treated with re-
combinant IL-17A relative to ve-
hicle alone at both time points
(Figs. 1A and 1B). Serum cardiac troponin T (cTnT) level, an
ndex of myocyte injury, was also significantly lower in the
nti–IL-17A mAb group and higher in the recombinant
nterleukin (rIL)-17A group (Online Fig. 3A).
To determine the effect of IL-17A on cardiac function
fter I/R and to demonstrate the clinical relevance of our
ndings, we measured ejection fraction (EF) and fractional
hortening (FS) by echocardiography. The EF and FS were
oth remarkably reduced at 1 day and 3 days after myocar-
ial I/R compared with the sham group. Furthermore,
reatment with anti–IL-17A mAb increased EF and FS
fter 1 day and 3 days reperfusion, indicating improved
ardiac function. Consistent with infarct size, a marked
eterioration of cardiac function, as shown by a decrease of
F and FS, was observed in the rIL-17A group (Figs. 1C
nd 1D). To test whether IL-17A affects hemodynamic
Abbreviations
and Acronyms
AAR  area at risk
cTnT  cardiac troponin T
EC  endothelial cell
EF  ejection fraction
ELR  glutamic
acid–leucine-arginine
FS  fractional shortening
H2O2  hydrogen peroxide
ICAM  inter-cellular
adhesion molecule
IL  interleukin
I/R  ischemia-reperfusion
KC  cytokine-induced
neutrophil chemoattractant
LIX  lipopolysaccharide-
induced CXC chemokine
LV  left
ventricle/ventricular
LVEDP  left ventricular
end-diastolic pressure
mAb  monoclonal
antibody
MIP  macrophage
inflammatory protein
mRNA  messenger
ribonucleic acid
rIL  recombinant
interleukin
TCR  T cell
receptor-positive
TUNEL  terminal
deoxynucleotidyl-
transferase mediated dUTP
nick-end labelingroperties, we measured left ventricular end-diastolic pres-
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Role of IL-17A in Myocardial I/R Injury January 24, 2012:420–9sure (LVEDP) and the derivative of LV pressure (dP/dt)
with a Millar catheter (SPR-671, Millar Instruments,
Houston, Texas). The LV hemodynamic statuses were
augmented in the anti–IL-17A mAb-treated group com-
pared with the isotype group. Specifically, LVEDP was
lower, whereas maximum and minimum dP/dt, the indexes
of contractility, were increased in the anti–IL-17A mAb-
treated group. Conversely, treatment with rIL-17A led to a
reduction of dP/dt and an elevation of LVEDP (Table 1).
Taken together, changes in the level of IL-17A can have
profound reciprocal effects on myocardial I/R injury, in
terms of both infarct area and cardiac function.
IL-17A knockout ameliorates myocardial I/R injury. To
elucidate the impact of IL-17A on myocardial I/R injury in
the genetically IL-17A free situation, we compared myo-
cardial I/R injury levels between Il17a–/– and wild-type
Figure 1 IL-17A Neutralization and Repletion Affected Mouse M
(A) Representative images of left ventricular (LV) slices from different groups at 1
(AAR) in red, and the infarct area in white. (B) Quantification of infarct size of myo
echocardiography images of the LV 1 d after reperfusion. (D) Ejection fraction and
versus isotype; §p  0.05; §§p  0.01 versus vehicle. IL  interleukin; I/R  iscyocardial I/R Injury
day (d) after reperfusion. The nonischemic area is indicated in blue, the area at risk
cardial tissues 1 day or 3 d after reperfusion (n  6 to 8). (C) Representative M-mode
LV fractional shortening (n  8). **p  0.01 versus sham; †p  0.05; ‡p  0.01
hemia/reperfusion.57BL/6 mice. Before surgery, we excluded the possibilityHemodynamic Status Measurementsof Myocardial I/R MiceTable 1 Hemodynamic Status Measurementsof Myocardial I/R Mice
Reperfusion Time
(Day)
LVEDP
(mm Hg)
dP/dtmax
(mm Hg/s)
dP/dtmin
(mm Hg/s)
Sham 1 2.7 0.6 5,786 289 5,471 238
Isotype 1 8.8 0.8* 3,760 257* 3,575 218*
Anti–IL-17A 1 4.4 0.6† 4,846 245‡ 4,412 263‡
Vehicle 1 8.4 0.8* 3,945 298* 3,743 304*
rIL-17A 1 14.6 1.3§ 2,447 165§ 2,727 345
Sham 3 3.3 0.3 5,488 247 5,659 336
Isotype 3 9.2 0.9* 3,662 254* 3,320 192*
Anti–IL-17A 3 4.8 0.4† 4,763 325‡ 4,617 166†
Vehicle 3 9.0 1.3* 3,759 201* 3,627 166*
rIL-17A 3 15.7 1.2§ 2,450 244§ 2,683 275
Values are mean SEM. N 6 to 8. *p 0.01 versus sham; †p 0.05 ; ‡p 0.01 versus isotype;
p  0.05; §p  0.01 versus vehicle.
IL  interleukin; I/R  ischemia-reperfusion; LVEDP  left ventricular end-diastolic pressure.
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January 24, 2012:420–9 Role of IL-17A in Myocardial I/R Injuryof cardiac abnormality in Il17a–/– mice by echocardiogra-
phy. Echocardiographic parameters of Il17a–/– mice were
omparable to those of wild-type mice (Online Table 3).
he Il17a–/– and wild-type mice were then subjected to
myocardial I/R. The extent of injury and heart functions
were assayed 1 day after initiation of reperfusion. With
similar AAR, the infarct size/AAR was significantly smaller
in Il17a–/– than in wild-type mice (Figs. 2A and 2B). Less
serious injury was also manifested by lower levels of serum
cTnT in Il17a–/– mice (Online Fig. 3B). In parallel, we
observed improved cardiac function, as indicated by elevated
EF and FS, in Il17a–/– mice after myocardial I/R compared
ith wild-type (Figs. 2C and 2D). This protection was also
emonstrated by hemodynamic measurements. The
Figure 2 IL-17A Knockout Ameliorated Myocardial I/R Injury
(A) Representative images of LV slices from wild-type (WT) and Il17a–/– mice at 1 day
(C) Representative M-mode images of the LV after sham and myocardial I/R from WT
versus WT. Abbreviations as in Figure 1.VEDP was lower, whereas LV dP/dt was higher inl17a–/– mice at 1 day after reperfusion (Table 2). These
esults confirm that IL-17A plays a pathogenic role in
yocardial I/R injury.
Hemodynamic Status Measurementsof Il17a–/– Mice After I/RTable 2 Hemodynamic Status Measurementsof Il17a–/– Mice After I/R
Reperfusion Time
(Day)
LVEDP
(mm Hg)
dP/dtmax
(mm Hg/s)
dP/dtmin
(mm Hg/s)
WT sham 1 3.0 0.5 5,898 282 5,564 172
WT I/R 1 8.36 1.1 3,832 155 3,534 157
Il17a–/– sham 1 2.8 0.4 5,784 291 5,369 148
Il17a–/– I/R 1 4.3 0.6* 4,903 265† 4,717 172*
I/R. (B) Quantification of infarct size of myocardium 1 day after reperfusion (n  8).
7a–/– mice. (D) Ejection fraction and LV fractional shortening (n  8). **p  0.01after
and Il1Values are mean  SEM. N  8. *p  0.01; †p  0.05 versus wild-type (WT).
Abbreviations as in Table 1.
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Role of IL-17A in Myocardial I/R Injury January 24, 2012:420–9IL-17a facilitates cardiomyocyte apoptosis after I/R in
vivo or oxidative stress in vitro. Apoptosis contributes
significantly to myocardial I/R injury (16). We hypothesized
that the role of IL-17A on myocardial I/R is associated with
effects on cardiomyocyte apoptosis. To test this hypothesis,
we carried out terminal deoxynucleotidyl-transferase medi-
ated dUTP nick-end labeling (TUNEL) of LV sections
from different experiment groups at 3 h after myocardial
I/R. As shown in Figures 3A and 3B, anti–IL-17A mAb
treatment remarkably decreased the number of TUNEL-
positive cardiomyocytes compared with control, suggesting
that IL17A neutralization inhibited the extent of cardiomy-
Figure 3 IL-17A–Mediated Cardiomyocyte Apoptosis In Vivo an
(A) Representative photographs of terminal deoxynucleotidyl-transferase mediated
reperfusion. Apoptotic nuclei were identified by TUNEL staining (green), cardiomyo
phenylindole staining (blue). Arrowheads indicate apoptotic cardiomyocytes. Scale
(n  4 to 5). (C) Caspase 3 activity in myocardium was assessed after 3 h of rep
†p  0.05; ‡p  0.01 versus control. (D) Mouse neonatal cardiomyocyte apopto
cates TUNEL positive cells. Results are representative of 3 independent assays. S
H2O2()IL-17A(-). (E) Real-time polymerase chain reaction (PCR) determined mous
The results were expressed as Bax/Bcl-2 ratio. *p  0.05; **p  0.01 versus co
dium. The results were expressed as ratio of Bax/Bcl-2. **p  0.01 versus shamocyte apoptosis. In contrast, repletion of IL-17A conferredthe opposite effect. Caspase 3 activity determined by a
caspase colorimetric assay from ischemic myocardium was
concomitantly down-regulated by anti–IL-17A mAb and
up-regulated by rIL-17A (Fig. 3C). These data indicate
that IL-17A has a pro-apoptotic effect on cardiomyocytes
after myocardial I/R in vivo.
To test whether IL-17A directly induces cardiomyo-
cyte apoptosis, we used primary cultures of neonatal
mouse ventricular myocytes that co-expressed IL-17RA
and IL-17RC, as detected by real-time polymerase chain
reaction and Western blot (Online Figs. 4A and 4B).
Cardiomyocytes were cultured with or without hydrogen
itro
nick-end labeling (TUNEL)-stained heart sections from different groups after 3-h
y anti-sarcomeric actin antibody (red), and total nuclei by 4’,6-diamidino-2-
0 mm. (B) Percentages of TUNEL-positive nuclei over total number of nuclei
n, and the values were normalized to sham (n  5); **p  0.01 versus sham;
er hydrogen peroxide (H2O2) and different doses of IL-17A. Brown staining indi-
ar: 100 mm. *p  0.05; **p  0.01 versus H2O2(-)IL-17A(-); ‡p  0.01 versus
atal cardiomyocyte Bcl-2 and Bax messenger ribonucleic acid (mRNA) levels.
(F) Real-time PCR determined mRNA level of Bcl-2 and Bax in ischemia myocar-
0.05 versus control. Abbreviations as in Figure 1.d In V
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; †p peroxide (H2O2), a potent inducer of oxidative stress
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January 24, 2012:420–9 Role of IL-17A in Myocardial I/R Injury(17), in the presence or absence of rIL-17A. As expected,
H2O2 treatment increased the frequency of apoptotic
cardiomyocytes, whereas IL-17A incubation further aug-
mented apoptosis. Interestingly, incubation with IL-17A
alone also induced apoptosis in a dose-dependent manner
(Fig. 3D). Taken together, these data indicate that IL-17A has
a direct pro-apoptotic effect on cardiomyocytes.
To understand mechanisms through which IL-17A in-
duces cardiomyocyte apoptosis, we examined expression of
the Bcl-2 family by real-time polymerase chain reaction.
The Bax/Bcl-2 ratio was significantly increased in cardio-
myocytes exposed to H2O2. Interleukin-17A alone also
increased the Bax/Bcl-2 ratio, which was further elevated
under an oxidative stress situation. Administration of
rIL-17 in vivo similarly increased the Bax/Bcl-2 ratio after
myocardial I/R, whereas that of anti–IL-17A mAb de-
creased the ratio (Figs. 3E and 3F, Online Fig. 5). These
results show that IL-17A induces cardiomyocyte apoptosis,
at least in part, through the regulation of pro- to anti-
apoptotic protein ratio of Bcl-2 family.
IL-17A mediates neutrophil recruitment through regulation
of CXC glutamic acid–leucine-arginine chemokine expression
after I/R in vivo and oxidative stress in vitro. Neutrophil
infiltration is a hallmark of inflammatory injury after myo-
cardial I/R (17), and 1 of the main functions of IL-17A is
neutrophil recruitment (18). As determined by myeloper-
oxidase activity and fluorescence activated cell sorting anal-
ysis of CD11bGr-1 neutrophils, myocardial I/R induced
surge in neutrophil recruitment to myocardium. Anti–IL-
7A mAb treatment reduced neutrophil recruitment,
hereas treatment with rIL-17A promoted this effect (Figs.
A to 4C).
The CXC glutamic acid–leucine-arginine (ELR)
chemokines KC, MIP-2, and LIX are not only potent
neutrophil chemoattractants but also IL-17A target genes
(19). Myocardial I/R caused a significant induction of
mRNA and protein levels of all 3 chemokines, consistent
with increased neutrophil infiltration. Moreover, neutraliza-
tion or repletion of IL-17A had the opposite effect on
expression of these chemokines after myocardial I/R (Fig. 4D,
Online Fig. 6A). Interleukin-17A also increased expression
of cardiomyocyte of these 3 chemokines, in vitro as deter-
mined by enzyme-linked immunoadsorbent assay. Stimula-
tion with IL-17A in addition to H2O2 led to a dose-
dependent potentiation of the effect of H2O2, markedly
up-regulating expression of these chemokines. Pre-
incubation with anti–IL-17A Ab could completely abolish
IL-17A activity (Fig. 4E, Online Fig. 6B). Furthermore, in
vitro neutrophil migration assay showed a marked enhance-
ment of neutrophil migration to media from cells treated
with IL-17A or H2O2 alone and was synergistically en-
anced by conditioned media from cells treated with both
gents (Fig. 4F). The activity of IL-17A could be com-
letely abolished by anti–IL-17A mAb but not isotype
Ab, indicating an IL-17A–specific effect. eL-17A regulates inter-cellular adhesion molecule-1 and
-selectin expression and stimulates endothelial activation
nd neutrophil-endothelial cell adhesion. Adhesion mole-
ule expression, an indicator of endothelium activation, is a
rerequisite for neutrophil-endothelium adherence, which
n turn contributes to myocardial I/R injury (20). To further
xplore the mechanisms by which IL-17A affects myocar-
ial I/R injury, we focused on inter-cellular adhesion mol-
cule (ICAM)-1 and E-selectin expression. After 30 min of
schemia and 3 h of reperfusion, we detected a substantial
ncrease of ICAM-1 mRNA level and a moderate but
ignificant increase of E-selectin mRNA levels within I/R
yocardium. Treatment with anti–IL-17A mAb attenuated
his induction, whereas rIL-17A treatment had the opposite
ffect (Fig. 5A). This effect of IL-17A on the expression of
CAM-1 and E-selectin was further confirmed by Western
lotting (Online Fig. 6C). As to the cellular level: stimula-
ion with IL-17A led to a higher surface expression of
CAM-1 and E-selectin on endothelial cells (ECs), as
etected by cell-based enzyme-linked immunoadsorbent
ssay and an increased adherence of neutrophils to ECs as
etected by neutrophil-EC adhesion assays. Moreover,
ddition of IL-17A to H2O2 led to a potentiation of the
ncreased ICAM-1 and E-selectin surface expression and
eutrophil adherence caused by H2O2 alone. When anti–
IL-17A mAb was added, this augmentation could be
absolutely blocked (Figs. 5B to 5D, Online Fig. 6D).
Discussion
The present study reveals a critical role for IL-17A in
mediating mouse myocardial I/R injury. Myocardial infil-
trated  T lymphocytes but not Th17 cells were a major
ource of IL-17A. Anti–IL-17A mAb treatment or IL-17A
nockout markedly ameliorated I/R injury, which was
ssociated with a reduction in cardiomyocyte apoptosis and
eutrophil infiltration. Repletion of exogenous IL-17A
nduced the opposite effect. In vitro experiments demon-
trated that IL-17A could induce cardiomyocyte apoptosis
hrough regulation of the Bax/Bcl-2 ratio. Moreover, IL-
7A enhanced neutrophil infiltration by promoting EC
-selectin and ICAM-1 expression and inducing CXC
hemokine-mediated neutrophil migration.
Ischemia-reperfusion triggers a vigorous inflammatory
esponse, augmented by the generation and release of
arious cytokines, chemokines, and adhesion molecules,
hich ultimately exacerbates tissue injury (21). Increasing
vidence indicates that the elements of both adaptive
mmunity and innate immunity participate in I/R injury
22). Notably, IL-17A acts as a bridge between adaptive and
nnate immunity through the potent induction of a gene
xpression program typical of the inflammatory response,
resenting a unique position in the immune response
rocess (3). This finding has prompted new insight into
he role of IL-17A in I/R injury. A growing body of
vidence demonstrates that IL-17A is involved in the
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Role of IL-17A in Myocardial I/R Injury January 24, 2012:420–9immune response during tissue I/R injury in brain, kidney,
and intestine (13–15). However, little was previously known
about myocardial I/R, although IL-17A is involved in the
pathogenesis of diverse cardiovascular diseases (7–12). Most
importantly, we have found elevated circulating levels of
IL-17A in patients with acute myocardial infarction (23).
Therefore, we focused on IL-17A in myocardial I/R with a
mouse model. Here, we observed elevated IL-17A in the
myocardium beginning at 1 h after I/R, peaking at 24 h, and
decreasing thereafter, which suggests that IL17A acts in the
Figure 4 IL-17A Increased Cardiac Neutrophil Recruitment and
Mice were assessed for chemokine expression and neutrophil infiltration at 3 h af
number of CD11bGr-1 neutrophils infiltrated in myocardium were analyzed by flo
phils infiltrated in myocardium. (D) Lipopolysaccharide-induced CXC chemokine (LI
protein-2 (MIP-2) mRNA levels were analyzed by real-time PCR. **p  0.01 versus
mined mouse cardiomyocytes KC, MIP-2, and LIX levels in the supernatants. (F) N
alone. *p  0.05; **p  0.01 versus medium; ‡p  0.01 versus H2O2; §§p  0
repeated 3 times. N  4 to 5. Abbreviations as in Figures 1 and 3.early stages of myocardial I/R.Although prior studies of IL-17A have focused largely on
CD4 Th17 cells, several reports indicate that T cells are
also a major source of this cytokine (4). In our study, most
of the IL-17A cells were CD3 T lymphocytes. To our
urprise, approximately 70% of the IL-17A–producing T
ymphocytes were CD4- but TCR. The differentiation
f Th17 cells from naïve-CD4 cells usually takes several
ays in vivo and is currently thought to depend on TCR
ngagement. However, IL-17–producing T cells can
immediately respond to stimuli—such as pathogens or
ation
ocardial I/R. (A) Cardiac myeloperoxidase activity in tissue samples. (B) The
metry. (C) The representative flow cytometry dot plots of CD11bGr-1 neutro-
okine-induced neutrophil chemoattractant (KC), and macrophage inflammatory
; ‡p  0.01 versus control. (E) Enzyme-linked immunoadsorbent assay deter-
hil migration, means  SEM. The value was normalized relative to medium
rsus IL-17A; #p  0.05; ##p  0.01 versus IL-17A/H2O2. All experiments wereMigr
ter my
w cyto
X), cyt
sham
eutrop
.01 veIL-1/IL-23—with no need for prior stimulation via the
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January 24, 2012:420–9 Role of IL-17A in Myocardial I/R InjuryTCR and produce high amounts of IL-17A within hours
(24). It is no wonder, considering the nearly instantaneous
elevation of IL-17A in myocardium after I/R, that T
lymphocytes but not Th17 cells were a major source of
IL-17A, which is consistent with cerebral I/R (13). How-
ever, IL-17A–producing cells detected in kidneys after 3 h
Figure 5 IL-17A–Mediated Neutrophil-EC Adhesion
(A) Mice were assessed for myocardium inter-cellular adhesion molecule (ICAM-1)
0.01 versus sham; †p  0.05; ‡p  0.01 versus control. (B) Mouse myocardial e
enzyme-linked immunoadsorbent assay, as indicated by the optical density 450 nm
Representative photomicrograph of neutrophils adhering to ECs. Neutrophils are id
0.05; **p  0.01 versus medium; ‡p  0.01 versus H2O2; §§p  0.01 versus I
ations as in Figures 1 and 3.of reperfusion were CD11bGR-1 neutrophils (14),which differs from our results that little of IL-17A–
producing cells are neutrophils. In intestinal I/R, although
Edgerton et al. (15) focused on CD4 T cells, they only
examined the co-localization of CD3 and IL-17A but
performed no further examination of T cell subsets. This
discrepancy might be attributed to differences between
E-selectin expression by real-time PCR at 3 h after I/R (n  4 to 5). **p 
elial cell (EC) expression of ICAM-1 and E-selectin was measured by a cell-based
Neutrophil adhesion on ECs was determined by fluorescence microscopy. (D)
d by green fluorescence. Scale bar: 50 mm. Values are means  SEM; *p 
#p  0.05 versus IL-17A/H2O2. All experiments were repeated 3 times. Abbrevi--1 and
ndoth
. (C)
entifie
L-17A;tissues of I/R model.
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Role of IL-17A in Myocardial I/R Injury January 24, 2012:420–9The Il17a–/– mice showed a significant reduction in
infarct volume after cerebral I/R (13). The Il17a–/– and
l17r–/– mice also showed protective effects on kidney
function and morphology after renal I/R. Such protection
was also observed by treatment with neutralizing anti–IL-
17A mAb (14). In the present study, both neutralization of
IL-17A just before induction of reperfusion and IL-17A
genetic deficiency markedly ameliorated I/R injury, as dem-
onstrated by reduced infarct size, cTnT levels, and improved
cardiac function, whereas exogenous IL-17A significantly
exacerbated I/R injury, demonstrating a critical role for
IL-17A in myocardial I/R injury.
Apoptosis has been proposed to be an important mech-
anism for a significant amount of cell death in reperfused
ischemic myocardium (16). It could be regulated by oxygen
free radicals, cytokines such as TNF- and IL-6, and
neutrophil accumulation (25). The Bcl-2 family consists of
pro- and anti-apoptotic members. The balance between
pro-apoptotic and anti-apoptotic proteins determines the
possibility of cells to either survive or undergo apoptosis
after a certain stimulus or injury. IL-17A has been shown to
induce vascular smooth muscle cell and airway epithelial cell
apoptosis, but it has no effect on keratinocyte and osteoblast
cell apoptosis (9,26–28). Our in vivo study showed that
neutralization or repletion of IL-17A could regulate cardi-
omyocyte apoptosis, as confirmed by the change of TUNEL
positive cardiomyocytes, caspase-3 activity, and the ratio of
pro-apoptotic (Bax) and anti-apoptotic (Bcl-2) proteins.
Interleukin-17A might trigger apoptosis directly in cardio-
myocytes or indirectly as a mediator that orchestrates other
factors. Our in vitro study further confirmed that IL-17A
had direct pro-apoptosis effect on cardiomyocyte. When the
cardiomyocytes are exposed to oxidative stress, extrinsic and
intrinsic signal pathways are activated, Fas mRNA and
Bcl-2 family proteins are up-regulated, and the redox state
is changed, which can ultimately drive cardiomyocyte into
apoptosis (25,29,30). The regulation of caspase-3 activity
and ratio of Bax/Bcl-2 demonstrated that IL-17A activated
intrinsic signal pathways. Remarkably, myocardial IL-17R
expression was not affected by I/R in vivo or oxidative stress
in vitro (data not shown), therefore the mechanisms
through which IL-17A alone or interaction with oxidative
stress modifies the apoptosis signal pathway in myocardial
I/R remain to be elucidated.
Neutrophil recruitment plays a major role in myocardial
damage after I/R (18). Neutrophil chemotaxis and activa-
tion might be strongly regulated by CXC chemokines,
particularly ELR chemokines with the tripeptide ELR
otif (31). Interestingly, IL-17A specifically induced the
xpression of all ELRCXCL chemokines (CXCL1,
CXCL2, CXCL3, CXCL5, CXCL6, and CXCL8) in
cultured human synoviocytes but had no effect on the
expression of non-ELR CXC chemokines (CXCL9,
CXCL10, and CXCL11) (32). Interleukin-17A has also
been shown to induce KC, MIP-2, and LIX, which are
rodent homologs of CXCL1, CXCL2, and CXCL5, inmouse osteoblastic cells (33) and lung fibroblasts (34).
Moreover, the importance of ELRCXC chemokines in
yocardial I/R has been implicated in vivo (35). Here, we
ound that inhibition of IL-17A markedly decreased cardiac
IX, KC, and MIP-2 expression and neutrophil infiltration
n mouse I/R myocardium, whereas exogenous IL-17A
ncreased LIX, KC, and MIP-2 expression and neutrophil
nfiltration in mouse I/R myocardium. In vitro experiments
emonstrated that IL-17A could enhance cardiomyocyte
IX, KC, and MIP-2 production and neutrophil migration
o the supernatant from conditioned cardiomyocytes. Taken
ogether, these results indicate that IL-17A contributes to
yocardial I/R injury at least partially through the regula-
ion of neutrophil infiltration to the myocardium via CXC
hemokine expression.
The neutrophil-endothelium interaction is critical for
eutrophil-mediated inflammation. The molecular interac-
ions required for neutrophils to cross the endothelium are
egulated via the expression of adhesion molecules on the
ndothelium (18). E-selectin is a key molecule for rolling,
hereas ICAM-1 is important in adhesion. Deficiency in
ither ICAM-1 or E-selectin expression results in a marked
eduction in neutrophil accumulation and myocardial injury
fter I/R (36). IL-17A was reported to be a potential upstream
nducer of ICAM-1 and E-selectin in lung microvascular ECs
37) and human umbilical vein ECs (19). We found that
nti–IL-17A mAb and rIL-17A treatments regulate the ex-
ression of ICAM-1 and E-selectin in I/R myocardium at
oth mRNA and protein levels. In vitro studies showed that
timulation with IL-17A resulted in endothelial activation as
evealed by elevated surface expression of E-selectin and
CAM-1 as well as neutrophil-endothelial adhesion. These
esults, along with the neutrophil migration data, support the
otion that IL-17A has a potent effect on neutrophil recruit-
ent and adherence, which are critical processes in myocardial
/R injury.
onclusions
e have presented evidence that IL-17A produced primar-
ly by T cells plays a pathogenic role in myocardial I/R
njury by inducing cardiomyocyte apoptosis and neutrophil
nfiltration. These data suggest a novel IL-17A-dependent
athway by which the immune system might influence the
yocardial I/R injury. Control of IL-17A production might be
f benefit for minimizing I/R-instigated myocardial damage.
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please see the online version of this article.
